

Cambium Bio Limited

ABN 13 127 035 358

ASX Announcement

23 May 2024

Notice of Share Consolidation

Sydney, Australia; 23 May 2024: Cambium Bio Limited (ASX:CMB) (**Cambium Bio** or **Company**), a clinical-stage regenerative medicine company focusing on the development of innovative biologics for ophthalmology and tissue repair applications, is pleased to announce its intention to undertake a consolidation of capital of the Company at a ratio of 100:1, subject to receipt of shareholder approval ("Consolidation") at a General Meeting to be held on Tuesday, 25 June 2024

As at today's date, the Company has **766,092,285** Shares on issue with a market capitalisation of approximately **\$5.36 million**. If the issue of Shares contemplated under the full Tranche 2 Placement proceeds, the Company will have on issue **1,193,067,757** Shares.

The Directors believe that the Consolidation will result in a more appropriate and effective capital structure for the Company and a Share price that is more appealing to a wider range of investors.

If the Resolution is passed, every hundred (100) Shares on issue will be consolidated into one (1) Share (subject to rounding).

Overall, this will result in the number of Shares on issue (based on share capital as at today's date) reducing from 766,092,285 to approximately 7,660,923 (subject to rounding).

As at today's date, the Company has on issue the following convertible securities:

- 30,162,833 options over Shares.

In accordance with Listing Rule 7.21 and the terms of the options, if the Resolution is passed, the Consolidation will result in the number of options being consolidated in a manner determined by the Board so that the relevant holder of any options does not receive a benefit that holders of Shares do not receive.

If approved by Shareholders, the proposed Consolidation will take effect in accordance with the following timetable (as set out in Appendix 7A (paragraph 7) of the Listing Rules:

Event	Indicative Date*
Announcement of Consolidation, lodgment of Appendix 3A.3 and notice of General Meeting despatched to Shareholders	23 May 2024
Date of General Meeting. Shareholders pass Resolution 5 to approve the Consolidation.	25 June 2024
Effective date of Consolidation	2 July 2024
Last day of trading in pre-Consolidation Shares.	3 July 2024
If agreed by ASX, trading in post-Consolidation Shares commences on a deferred settlement basis.	4 July 2024
Record date for Share Consolidation (being the last day for the Company to register transfers of Shares on a pre-Consolidation basis.	5 July 2024
First day for the Company to update its register and send holding statements to Shareholders reflecting the change in number of Shares they hold following completion of the Share Consolidation.)	8 July 2024
Last day for the Company to update its register and send holding statements to Shareholders reflecting the change in number of Shares they hold following completion of the Share Consolidation, and to notify ASX that this has occurred.	12 July 2024

* The above dates are indicative only and subject to change.

About Cambium Bio Limited (formerly named Regeneus Ltd)

Cambium Bio Limited (ASX:CMB) is a Sydney-based clinical-stage regenerative medicine company focusing on the development of innovative biologics for ophthalmology and tissue repair applications. The Company's proprietary technology, based on human platelet lysate, is being leveraged to create a pipeline of novel therapeutics, with a primary focus on ophthalmology. Cambium Bio's lead product candidate, Elate Ocular®, is being developed to address significant unmet medical needs in the treatment of dry eye disease. In addition, the Company's stem cell platform, Progenza™, is being applied to the development of therapies for knee osteoarthritis and other tissue repair indications. Cambium Bio is committed to advancing its pipeline through clinical development and commercialization, with the goal of providing transformative treatments to improve patient outcomes. For more information about the Company and its programs, please visit www.cambium.bio

Authorisation & Additional information

This announcement was authorised by the Board of Directors of Cambium Bio Limited.